Related Experiment Video
Updated: Nov 17, 2025
06:33
Production of Human CRISPR-Engineered CAR-T Cells
Published on: March 15, 2021
13.7K
Using CRISPR to enhance T cell effector function for therapeutic applications.
1Independent Scientist, the Netherlands.
Cytokine: X
|February 19, 2021
Summary
CRISPR/Cas9 genome editing enhances T cell effector functions to improve cancer immunotherapy. This technology modifies T cells to boost their cancer-fighting abilities, showing promise in clinical trials.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- T cells are crucial for immune defense against pathogens and cancer.
- Tumors employ inhibitory mechanisms that impair T cell effector functions, hindering cancer elimination.
- Current limitations in T cell-mediated cancer control necessitate novel therapeutic strategies.
Purpose of the Study:
- To review recent advances in T cell genomic engineering using CRISPR/Cas9 technology.
- To discuss the enhancement of T cell effector function for therapeutic cancer immunotherapy.
- To provide an overview of available genome editing techniques for T cell modification.
Main Methods:
- Utilizing CRISPR/Cas9 technology for T cell genomic modification.
- Engaging post-transcriptional mechanisms to enhance T cell cytokine production.
- Retargeting T cell antigen specificity and modifying responses to inhibitory signals.
Main Results:
- CRISPR/Cas9-mediated engineering can augment T cell effector functions.
- Modified T cells demonstrate enhanced potential for cancer immunotherapy.
- The first clinical trial with CRISPR/Cas9-modified human T cells has been successfully conducted.
Conclusions:
- CRISPR/Cas9 genome editing offers promising novel strategies for cancer immunotherapy.
- Enhancing T cell effector function through genomic engineering can overcome tumor-induced suppression.
- Further development and application of these techniques hold significant therapeutic potential.
Keywords:
AP-1, activator protein 1ARE, AU-rich elementARE-Del, deletion of the 3′UTR AREs from the Ifng/IFNG geneCAR T cellsCAR, Chimeric Antigen ReceptorCRISPRCRISPR, Clustered Regularly Interspaced Short Palindromic RepeatCRS, cytokine release syndromeCTLA-4, cytotoxic T-lymphocyte-associated protein 4Cas, CRISPR-associatedCas9CytokinesDGK, Diacylglycerol kinaseDHX37, DEAH-box helicase 37EBV, Epstein Barr virusFOXP3, Forkhead box P3GATA, GATA binding proteinGenome editingIFN, interferonIL, interleukinLAG-3, Lymphocyte Activating 3NF-κB, nuclear factor of activated B cellsPD-1, Programmed cell Death 1PD-L1, Programmed Death Ligand 1PTPN2, Protein Tyrosine Phosphatase Non-Receptor 2Pdia3, Protein Disulfide Isomerase Family A Member 3RBP, RNA-binding proteinRNP, ribonuclear proteinT cell effector functionT cellsTCR, T cell receptorTGF, transforming growth factorTIL, Tumor Infiltrating LymphocyteTLRs, Toll-like receptorsTNF, tumor necrosis factorTRAC, TCR-α chainTRBC, TCR-β chainUTR, untranslated regiontTCR, transgenic TCR
Related Concept Videos
01:59CRISPR
54.7K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
54.7K
01:28CRISPR/Cas9 Genome Editing
975
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
975
02:31Homologous Recombination
58.9K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
58.9K
01:27Tumor Immunotherapy
856
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
856